Last reviewed · How we verify
xinzhijun
xinzhijun is a Small molecule drug developed by Xiangbei Welman Pharmaceutical Co., Ltd. It is currently in Phase 2 development. Also known as: Experimental, shumate.
Xinzhijun is a medication used to treat Respiratory Tract Infections and Urinary Tract Infections. It is a combination of cefotaxime and sulbactam sodium for injection.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | xinzhijun |
|---|---|
| Also known as | Experimental, shumate |
| Sponsor | Xiangbei Welman Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- xinzhijun CI brief — competitive landscape report
- xinzhijun updates RSS · CI watch RSS
- Xiangbei Welman Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about xinzhijun
What is xinzhijun?
Who makes xinzhijun?
Is xinzhijun also known as anything else?
What development phase is xinzhijun in?
Related
- Manufacturer: Xiangbei Welman Pharmaceutical Co., Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Experimental, shumate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing